The Evolution of Genetics: Alzheimer’s and Parkinson’s Diseases
Genetic discoveries underlie the majority of the current thinking in neurodegenerative disease. This work has been driven by the significant gains made in identifying causal mutations; however, the translation of genetic causes of disease into pathobiological understanding remains a challenge. The a...
Gespeichert in:
Veröffentlicht in: | Neuron (Cambridge, Mass.) Mass.), 2016-06, Vol.90 (6), p.1154-1163 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1163 |
---|---|
container_issue | 6 |
container_start_page | 1154 |
container_title | Neuron (Cambridge, Mass.) |
container_volume | 90 |
creator | Singleton, Andrew Hardy, John |
description | Genetic discoveries underlie the majority of the current thinking in neurodegenerative disease. This work has been driven by the significant gains made in identifying causal mutations; however, the translation of genetic causes of disease into pathobiological understanding remains a challenge. The application of a second generation of genetics methods allows the dissection of moderate and mild genetic risk factors for disease. This requires new thinking in two key areas: what constitutes proof of pathogenicity, and how do we translate these findings to biological understanding. Here we describe the progress and ongoing evolution in genetics. We describe a view that rejects the tradition that genetic proof has to be absolute before functional characterization and centers on a multi-dimensional approach integrating genetics, reference data, and functional work. We also argue that these challenges cannot be efficiently met by traditional hypothesis-driven methods but that high content system-wide efforts are required.
The piece by Singleton and Hardy describes the evolution and future of the identification and interpretation of genetic influences in neurodegenerative disease. It argues that maximizing the benefits of genetic progress requires a systematic and system wide approach to pathobiology. |
doi_str_mv | 10.1016/j.neuron.2016.05.040 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1808715510</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0896627316302513</els_id><sourcerecordid>4102007521</sourcerecordid><originalsourceid>FETCH-LOGICAL-c535t-61d9f2beea127901120a5099b207062c12e5a1c87e4f7606ccef87b612e422f93</originalsourceid><addsrcrecordid>eNqFkc9u1DAQhy0EokvhDRCKxIVLwow38R8OSNW2lEqVyqGcLa8zUb1k7WInlcqpr8Hr8SR42dIDB3oa-advZuT5GHuN0CCgeL9pAs0phoaXVwNdAy08YQsELesWtX7KFqC0qAWXywP2IucNALadxufsoESIoHDBVpdXVJ3cxHGefAxVHKpTCjR5lz9UR-OPK_JbSr_ufubKhr76YtM3H3IMf5Jjn8lmyi_Zs8GOmV7d10P29dPJ5epzfX5xerY6Oq9dt-ymWmCvB74mssilBkQOtgOt1xwkCO6QU2fRKUntIAUI52hQci1K3nI-6OUhe7efe53i95nyZLY-OxpHGyjO2aACJbHrEB5HpZZKliu0BX37D7qJcwrlIztKK2yV4IVq95RLMedEg7lOfmvTrUEwOx9mY_Y-zM6Hgc4UH6Xtzf3web2l_qHpr4ACfNwDVA534ymZ7DwFR71P5CbTR___Db8Ba9Wc7Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1799814862</pqid></control><display><type>article</type><title>The Evolution of Genetics: Alzheimer’s and Parkinson’s Diseases</title><source>MEDLINE</source><source>Cell Press Free Archives</source><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Singleton, Andrew ; Hardy, John</creator><creatorcontrib>Singleton, Andrew ; Hardy, John</creatorcontrib><description>Genetic discoveries underlie the majority of the current thinking in neurodegenerative disease. This work has been driven by the significant gains made in identifying causal mutations; however, the translation of genetic causes of disease into pathobiological understanding remains a challenge. The application of a second generation of genetics methods allows the dissection of moderate and mild genetic risk factors for disease. This requires new thinking in two key areas: what constitutes proof of pathogenicity, and how do we translate these findings to biological understanding. Here we describe the progress and ongoing evolution in genetics. We describe a view that rejects the tradition that genetic proof has to be absolute before functional characterization and centers on a multi-dimensional approach integrating genetics, reference data, and functional work. We also argue that these challenges cannot be efficiently met by traditional hypothesis-driven methods but that high content system-wide efforts are required.
The piece by Singleton and Hardy describes the evolution and future of the identification and interpretation of genetic influences in neurodegenerative disease. It argues that maximizing the benefits of genetic progress requires a systematic and system wide approach to pathobiology.</description><identifier>ISSN: 0896-6273</identifier><identifier>EISSN: 1097-4199</identifier><identifier>DOI: 10.1016/j.neuron.2016.05.040</identifier><identifier>PMID: 27311081</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Alzheimer Disease - genetics ; Alzheimer's disease ; Biomarkers ; Cloning ; Exome sequencing ; Genes ; Genetic Predisposition to Disease - genetics ; Genetics ; Genetics, Medical - trends ; Genome-wide association ; Genomes ; Humans ; Mutation ; Parkinson Disease - genetics ; Parkinson’s disease ; Research Design - trends ; Success</subject><ispartof>Neuron (Cambridge, Mass.), 2016-06, Vol.90 (6), p.1154-1163</ispartof><rights>2016</rights><rights>Published by Elsevier Inc.</rights><rights>Copyright Elsevier Limited Jun 15, 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c535t-61d9f2beea127901120a5099b207062c12e5a1c87e4f7606ccef87b612e422f93</citedby><cites>FETCH-LOGICAL-c535t-61d9f2beea127901120a5099b207062c12e5a1c87e4f7606ccef87b612e422f93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0896627316302513$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27311081$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Singleton, Andrew</creatorcontrib><creatorcontrib>Hardy, John</creatorcontrib><title>The Evolution of Genetics: Alzheimer’s and Parkinson’s Diseases</title><title>Neuron (Cambridge, Mass.)</title><addtitle>Neuron</addtitle><description>Genetic discoveries underlie the majority of the current thinking in neurodegenerative disease. This work has been driven by the significant gains made in identifying causal mutations; however, the translation of genetic causes of disease into pathobiological understanding remains a challenge. The application of a second generation of genetics methods allows the dissection of moderate and mild genetic risk factors for disease. This requires new thinking in two key areas: what constitutes proof of pathogenicity, and how do we translate these findings to biological understanding. Here we describe the progress and ongoing evolution in genetics. We describe a view that rejects the tradition that genetic proof has to be absolute before functional characterization and centers on a multi-dimensional approach integrating genetics, reference data, and functional work. We also argue that these challenges cannot be efficiently met by traditional hypothesis-driven methods but that high content system-wide efforts are required.
The piece by Singleton and Hardy describes the evolution and future of the identification and interpretation of genetic influences in neurodegenerative disease. It argues that maximizing the benefits of genetic progress requires a systematic and system wide approach to pathobiology.</description><subject>Alzheimer Disease - genetics</subject><subject>Alzheimer's disease</subject><subject>Biomarkers</subject><subject>Cloning</subject><subject>Exome sequencing</subject><subject>Genes</subject><subject>Genetic Predisposition to Disease - genetics</subject><subject>Genetics</subject><subject>Genetics, Medical - trends</subject><subject>Genome-wide association</subject><subject>Genomes</subject><subject>Humans</subject><subject>Mutation</subject><subject>Parkinson Disease - genetics</subject><subject>Parkinson’s disease</subject><subject>Research Design - trends</subject><subject>Success</subject><issn>0896-6273</issn><issn>1097-4199</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc9u1DAQhy0EokvhDRCKxIVLwow38R8OSNW2lEqVyqGcLa8zUb1k7WInlcqpr8Hr8SR42dIDB3oa-advZuT5GHuN0CCgeL9pAs0phoaXVwNdAy08YQsELesWtX7KFqC0qAWXywP2IucNALadxufsoESIoHDBVpdXVJ3cxHGefAxVHKpTCjR5lz9UR-OPK_JbSr_ufubKhr76YtM3H3IMf5Jjn8lmyi_Zs8GOmV7d10P29dPJ5epzfX5xerY6Oq9dt-ymWmCvB74mssilBkQOtgOt1xwkCO6QU2fRKUntIAUI52hQci1K3nI-6OUhe7efe53i95nyZLY-OxpHGyjO2aACJbHrEB5HpZZKliu0BX37D7qJcwrlIztKK2yV4IVq95RLMedEg7lOfmvTrUEwOx9mY_Y-zM6Hgc4UH6Xtzf3web2l_qHpr4ACfNwDVA534ymZ7DwFR71P5CbTR___Db8Ba9Wc7Q</recordid><startdate>20160615</startdate><enddate>20160615</enddate><creator>Singleton, Andrew</creator><creator>Hardy, John</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20160615</creationdate><title>The Evolution of Genetics: Alzheimer’s and Parkinson’s Diseases</title><author>Singleton, Andrew ; Hardy, John</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c535t-61d9f2beea127901120a5099b207062c12e5a1c87e4f7606ccef87b612e422f93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Alzheimer Disease - genetics</topic><topic>Alzheimer's disease</topic><topic>Biomarkers</topic><topic>Cloning</topic><topic>Exome sequencing</topic><topic>Genes</topic><topic>Genetic Predisposition to Disease - genetics</topic><topic>Genetics</topic><topic>Genetics, Medical - trends</topic><topic>Genome-wide association</topic><topic>Genomes</topic><topic>Humans</topic><topic>Mutation</topic><topic>Parkinson Disease - genetics</topic><topic>Parkinson’s disease</topic><topic>Research Design - trends</topic><topic>Success</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Singleton, Andrew</creatorcontrib><creatorcontrib>Hardy, John</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Neuron (Cambridge, Mass.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Singleton, Andrew</au><au>Hardy, John</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Evolution of Genetics: Alzheimer’s and Parkinson’s Diseases</atitle><jtitle>Neuron (Cambridge, Mass.)</jtitle><addtitle>Neuron</addtitle><date>2016-06-15</date><risdate>2016</risdate><volume>90</volume><issue>6</issue><spage>1154</spage><epage>1163</epage><pages>1154-1163</pages><issn>0896-6273</issn><eissn>1097-4199</eissn><abstract>Genetic discoveries underlie the majority of the current thinking in neurodegenerative disease. This work has been driven by the significant gains made in identifying causal mutations; however, the translation of genetic causes of disease into pathobiological understanding remains a challenge. The application of a second generation of genetics methods allows the dissection of moderate and mild genetic risk factors for disease. This requires new thinking in two key areas: what constitutes proof of pathogenicity, and how do we translate these findings to biological understanding. Here we describe the progress and ongoing evolution in genetics. We describe a view that rejects the tradition that genetic proof has to be absolute before functional characterization and centers on a multi-dimensional approach integrating genetics, reference data, and functional work. We also argue that these challenges cannot be efficiently met by traditional hypothesis-driven methods but that high content system-wide efforts are required.
The piece by Singleton and Hardy describes the evolution and future of the identification and interpretation of genetic influences in neurodegenerative disease. It argues that maximizing the benefits of genetic progress requires a systematic and system wide approach to pathobiology.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>27311081</pmid><doi>10.1016/j.neuron.2016.05.040</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0896-6273 |
ispartof | Neuron (Cambridge, Mass.), 2016-06, Vol.90 (6), p.1154-1163 |
issn | 0896-6273 1097-4199 |
language | eng |
recordid | cdi_proquest_miscellaneous_1808715510 |
source | MEDLINE; Cell Press Free Archives; Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Alzheimer Disease - genetics Alzheimer's disease Biomarkers Cloning Exome sequencing Genes Genetic Predisposition to Disease - genetics Genetics Genetics, Medical - trends Genome-wide association Genomes Humans Mutation Parkinson Disease - genetics Parkinson’s disease Research Design - trends Success |
title | The Evolution of Genetics: Alzheimer’s and Parkinson’s Diseases |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T01%3A59%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Evolution%20of%20Genetics:%20Alzheimer%E2%80%99s%20and%20Parkinson%E2%80%99s%20Diseases&rft.jtitle=Neuron%20(Cambridge,%20Mass.)&rft.au=Singleton,%20Andrew&rft.date=2016-06-15&rft.volume=90&rft.issue=6&rft.spage=1154&rft.epage=1163&rft.pages=1154-1163&rft.issn=0896-6273&rft.eissn=1097-4199&rft_id=info:doi/10.1016/j.neuron.2016.05.040&rft_dat=%3Cproquest_cross%3E4102007521%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1799814862&rft_id=info:pmid/27311081&rft_els_id=S0896627316302513&rfr_iscdi=true |